# Tasso

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tasso

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.tassoinc.com
- Total disclosed funding: $123M
- Latest round: Series B (Dec 16, 2021)
- Investors on record: 12

## About

Based in Washington, US, and founded in 2014 by Ben Casavant, and Erwin Berthier, Tasso, Inc. develops Tasso OnDemand, a self-testing kit that enables individuals to collect blood from their home and mail the samples back to the lab for analysis. In December 2021, Tasso, Inc. raised USD 100 million in a Series B funding led by RA Capital, with participation from D.E. Shaw & Co, InCube Ventures, Senvest Capital, and Silicon Valley Bank. Returning investors Cedars-Sinai Accelerator, Foresite Capital, Hambrecht Ducera Growth Ventures, J2 Ventures, and Merck Global Health Innovation Fund. As of December 2021, co-founder Ben Casavant is the CEO of Tasso, Inc. 

The product line of Tasso, Inc. includes Tasso+, Tasso-M20, and Tasso-SST. Tasso+ is a device that collects whole liquid blood samples for the use of various downstream applications. Tasso-M20 is a device that delivers whole dried blood samples from the patient to the lab. Tasso-SST is a single-use blood collection device that delivers whole liquid blood samples prepared without anticoagulation and allows an immediate separation of serum for antibody and other testings.

Tasso, Inc. plans to use its proceeds from a Series B funding to scale manufacturing and operations to meet the increased demand for its signature line of blood collection devices and high-quality, reliable decentralized health testing services.

## Funding rounds

- Series B, Dec 16, 2021, $100M — D. E. Shaw & Co, InCube Ventures, Merck Global Health Innovation Fund, Silicon Valley Bank, Hambrecht Capital, Foresite Capital, RA Capital Management, Senvest Capital, J2 Ventures, Cedars-Sinai Health Ventures
- Series A, Dec 19, 2019, $17M — Merck Global Health Innovation Fund, Hambrecht Capital, Foresite Capital, Techstars, Vertical Venture Partners, Cedars-Sinai Health Ventures
- Series A, Mar 5, 2019, $6.1M — Techstars, Vertical Venture Partners, Cedars-Sinai Health Ventures

## Investors

- Techstars (https://capitalatlas.ai/funds/techstars) — Series A
- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series A
- Cedars-Sinai Health Ventures — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A, Series B
- Hambrecht Capital (https://capitalatlas.ai/funds/hambrecht-capital) — Series A, Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B
- D. E. Shaw & Co (https://capitalatlas.ai/funds/d-e-shaw-co) — Series B
- InCube Ventures — Series B
- Silicon Valley Bank — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Senvest Capital (https://capitalatlas.ai/funds/senvest-capital) — Series B
- J2 Ventures (https://capitalatlas.ai/funds/j2-ventures) — Series B